GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two abstracts describing preclinical studies with GMI-1070 have been selected for oral presentations at the 51st Annual American Society of Hematology (ASH) meeting being held December 5-8 in New Orleans. Results of a Phase 1 clinical trial of GMI-1070 were also accepted for poster presentation.
